Sept 26 (Reuters) - Evaxion Biotech A/S :
* EVAXION SIGNIFICANTLY EXPANDS VACCINE DEVELOPMENT COLLABORATION WITH MSD
* EVAXION BIOTECH A/S - ENTERS OPTION AND LICENSE AGREEMENT WITH MSD
* EVAXION BIOTECH A/S - MSD GRANTED OPTION TO LICENSE EVAXION'S EVX-B2 AND EVX-B3
* EVAXION BIOTECH A/S - TO RECEIVE $3.2 MILLION UPFRONT, UP TO $10 MILLION IN 2025
* EVAXION BIOTECH A/S - ELIGIBLE FOR UP TO $592 MILLION PER PRODUCT IN MILESTONES
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments